AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs is setting up industry-leading growth.
The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.
The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.
|
Metric
|
AZN
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.86 | 89.00 | 83.48 |
Price/Book Value | 5.41 | 65.81 | 8.44 |
Price/Sales | 4.66 | 19.77 | 5.31 |
Price/Cash Flow | 21.26 | 92.46 | 20.97 |
|
Metric
|
AZN
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.58 | 0.52 | 0.68 |
Current Ratio | 0.82 | 0.94 | 1.25 |
Interest Coverage | 5.15 | 14.13 | 2.33 |
|
Metric
|
AZN
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 11.55% | 10.22% | 3.59% |
Return on Equity (Normalized) | 30.14% | 52.03% | 9.12% |
Return on Invested Capital (Normalized) | 18.47% | 19.27% | 5.88% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Bjmxgvdbb | Jjpf | $709.2 Bil | |
JNJ
| Johnson & Johnson | Wrjzhdz | Qqgf | $351.2 Bil | |
MRK
| Merck & Co Inc | Tqdxxdxc | Rqwy | $317.2 Bil | |
ABBV
| AbbVie Inc | Vbxvbfbw | Gzx | $291.6 Bil | |
RHHBY
| Roche Holding AG ADR | Zjhmqjmqx | Fld | $194.6 Bil | |
NVS
| Novartis AG ADR | Brmfnxjl | Sfrv | $189.7 Bil | |
PFE
| Pfizer Inc | Kfjxlxwf | Sscg | $143.8 Bil | |
AMGN
| Amgen Inc | Szhldygyr | Hvgx | $140.9 Bil | |
SNY
| Sanofi SA ADR | Kncnvsrk | Bdsm | $113.5 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)